Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach
Mirum Pharmaceuticals said its drug volixibat met the main goal in a 158-patient Phase 2b trial for primary sclerosing cholangitis, reducing itch scores more than placebo. Shares rose about 9% after the announcement. The company plans a pre-NDA meeting with the FDA this summer and aims to file for U.S. approval in the second half of 2026. No FDA-approved therapies currently exist for this rare liver disease.